Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 72-year-old man is evaluated in the clinic following a recent hospital admission for symptomatic ventricular tachycardia. During his hospitalization, he was initiated on oral amiodarone therapy to suppress further arrhythmias. His past medical history is significant for a mechanical aortic valve replacement, hypertension, and hyperlipidemia. His current home medications include warfarin, lisinopril, and atorvastatin. The patient is currently asymptomatic, and his vital signs are within normal limits. Which of the following are appropriate components of the monitoring and treatment evaluation plan for this patient? (Select all that apply)

  1. Reduce the maintenance dose of warfarin and reassess the international normalized ratio (INR) within one to two weeks.Cevap
  2. Obtain a baseline serum thyroid-stimulating hormone (TSH) level, with periodic reassessment during therapy.Cevap
  3. C
    Increase the daily dose of atorvastatin to counteract anticipated hepatic cytochrome P450 enzyme induction.
  4. D
    Monitor the patient's ongoing anticoagulation efficacy using the activated partial thromboplastin time (aPTT).
  5. E
    Discontinue the antiarrhythmic medication immediately if an isolated, asymptomatic elevation in serum aminotransferases up to 1.5 times the upper limit of normal is observed.

Cevap

The correct management steps involve reducing the warfarin dose to accommodate drug interactions and establishing baseline and ongoing monitoring of thyroid function (TSH).
Amiodarone is a potent inhibitor of several cytochrome P450 enzymes, most notably CYP2C9 and CYP3A4. Inhibition of CYP2C9 substantially decreases the clearance of warfarin, predictably raising the INR and the risk of hemorrhage; thus, a preemptive dose reduction of warfarin by 25% to 50% with close INR monitoring is standard practice. Furthermore, because amiodarone contains high amounts of iodine and causes direct cellular toxicity, it is strongly associated with both hypothyroidism and thyrotoxicosis. Consequently, obtaining a baseline serum TSH level, with subsequent periodic checks (e.g., every 3-6 months), is a mandatory component of the ongoing monitoring and treatment evaluation plan.

Adım Adım Çözüm

1
Identify high-risk drug-drug interactions involving amiodarone.
Amiodarone is identified as a potent inhibitor of CYP2C9 and CYP3A4, which will significantly increase serum concentrations of the patient's concurrent warfarin and atorvastatin.
Recognizing metabolic inhibition prevents life-threatening toxicity such as severe hemorrhage or rhabdomyolysis.
2
Adjust pharmacotherapy based on expected interactions.
The warfarin dose should be reduced preemptively by 25% to 50%, with close follow-up of the INR in 1 to 2 weeks.
Decreased warfarin clearance will lead to supratherapeutic INR levels if the dose is not proactively reduced.
3
Establish an ongoing surveillance plan for organ-specific adverse effects.
Baseline and periodic monitoring of TSH, along with pulmonary function testing and hepatic panels, is planned.
Amiodarone has a well-documented multi-organ toxicity profile, notably affecting the thyroid gland, lungs, and liver, requiring scheduled long-term evaluation.

Anahtar Kavram

Amiodarone initiation requires preemptive dose reductions of interacting drugs (e.g., warfarin via CYP2C9 inhibition) and mandatory baseline/periodic laboratory monitoring for intrinsic organ toxicities (e.g., TSH for thyroid dysfunction).
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru